Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
复制标题
鉴定一组血清 microRNA 作为早期检测肺腺癌的生物标志物
DOI：
10.7150/jca.16644
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Lou J
中科院分区：
文献类型：
--
作者：
Lv S;Xue J;Wu C;Wang L;Wu J;Xu S;Liang X;Lou J
前言：由于目前尚无敏感和特异的早期诊断肺腺癌的生物标志物，而且大多数AD患者是在疾病晚期才被诊断出来的，因此迫切需要建立一种有效的早期肺腺癌筛查方法。血清microRNAs(MiRNAs)已被证明是肿瘤诊断的新的非侵入性生物标志物，因此，我们研究了AD患者血清miRNA的谱，以确定差异表达的miRNAs作为AD早期检测的潜在生物标志物。患者和方法：收集180例AD患者和180例年龄和性别匹配的健康对照的血清样本。采用低密度阵列(LDA)技术，对20例患者和20例对照组的血清miRNA进行分析。为了验证所选择的miRNAs，使用了基于茎环的RT-qPCR方法，并检测了160名患者和160名对照的血清样本。结果：与对照组相比，AD患者血清样本中有11个miRNAs存在差异表达。其中筛选出6个AD患者的miR-103、miR-146a、miR-151、miR-21、miR-221、miR-222和miR-223。特别是，与健康对照组相比，前三位基因miR-146a、miR-222和miR-223在I/II期AD患者中显著表达。结论：一组含有miR-146a、miR-222和miR-223的miRNAs可作为AD早期诊断的无创性标志物。
Introduction: Since currently no sensitive and specific biomarkers for early detection of lung adenocarcinoma (AD) exist and the majority of AD patients are diagnosed at late stages of disease, the development of effective screening tests for early-stage lung AD is urgently needed. Serum microRNAs (miRNAs) have been documented as novel noninvasive biomarkers in tumor diagnosis; thus, we studied the profile of serum miRNA in AD patients in order to identify the differentially expressed miRNAs as potential biomarkers for early detection of AD. Patients and Methods: Serum samples were collected from 180 AD patients and 180 age- and sex-matched healthy controls. Serum miRNA profiling was performed by low-density array (LDA) using RNA extracted from blood samples of 20 patients and 20 controls. To validate the selected miRNAs, a stem-loop based RT-qPCR assay was used and serum samples from 160 patients and 160 controls were examined. Results: Profiling data showed 11 differentially expressed miRNAs in the serum samples from AD patients compared with the controls. Among them, 6 selected miRNAs in AD patients, including miR-103, miR-146a, miR-151, miR-21, miR-221, miR-222, and miR-223, were validated by RT-qPCR. In particular, the top three, miR-146a, miR-222, and miR-223, were confirmed to be significantly expressed in stage I/II AD patients compared with healthy controls. Conclusion: A panel of miRNAs with miR-146a, miR-222 and miR-223 could be used as potential noninvasive biomarkers for early detection of AD.